Table 1. Main characteristics of the studies included in the meta-analysis.
| Study | Trial design | Patients | Intervention | NV | NN | CR | |
|---|---|---|---|---|---|---|---|
| Acute phase | Delayed phase | ||||||
| Paul J. Hesketh, et al. 2003 [12] | parallelgroup double-blind | 520 | OND 32 mg iv + DXM 20 mg po APR 125 mg po + OND 32 mg iv + DXM 12 mg po |
DXM 8 mg po bid APR 80 mg po + DXM 8 mg po on day 2–3, DXM 8 mg on day 4 |
153/260 (58.9%) 210/260 (80.8%) |
124/260 (47.7%) 133/260 (51.2%) |
145/260 (55.8%) 196/260 (75.4%) |
| Sant P. Chawla, et al. 2001 [13] | parallelgroup double-blind | 258 | APR 125 mg + OND 32 mg iv + DXM 20 mg po Placebo po + OND 32 mg + DXM 20 mg |
APR 80 mg + DXM 8 mg Placebo po + DXM 8 mg |
102/132 (77.3%) 63/126 (50.0%) |
77/132 (58.3%) 46/126 (36.5%) |
96/132 (72.7%) 57/126 (45.2%) |
| Daniel Campos, et al. 2001 [14] | parallelgroup double-blind | 174 | GRA 10 μg/kg iv + DXM 20 mg po GRA 10 μg/kg + DXM 20 mg po + APR 400 mg po |
Placebo po APR 300 mg po |
26/90 (28.9%) 53/84 (63.1%) |
N/A | N/A |
| Sergio Poli-Bigelli, et al. 2003 [15] | parallelgroup double-blind | 523 | OND 32 mg iv + DXM 20 mg po APR 125 mg po + OND 32 mg po + DXM 12 mg po |
DXM 8 mg po bid APR 80 mg po + DXM 8 mg po on day 2–3, DXM 8 mg on day 4 |
126/263 (47.9%) 187/260 (71.9%) |
105/263 (39.9%) 138/260 (53.1%) |
123/263 (46.8%) 176/260 (67.7%) |
| P. J. Hesketh, et al. 2014 [16] | parallelgroup double-blind | 403 | PAL 0.5 mg po + DXM 20 mg po + placebo NETU 300 mg po + PAL 0.5 mg po + DXM 12 mg po APR 125 mg po + OND 32 mg po + DXM 12 mg po APR |
DXM 8 mg po bid DXM 4 mg po bid APR 80 mg po + DXM 8 mg po on day 2–3, DXM 8 mg on day 4 |
109/136 (80.1%) 124/135 (91.9%) 118/132 (89.4%) |
110/136 (80.9%) 122/135 (90.4%) 116/132 (87.9%) |
109/136 (80.1%) 122/135 (90.4%) 119/132 (90.2%) |
| H. Saito, et al. 2013 [17] | parallelgroup double-blind | 340 | FOS 150 mg iv + GRA 40 μg/kg iv + DXM 10 mg iv Placebo iv + GRA 40 μg/kg iv + DXM 20 mg iv |
DXM 4 mg iv on day 2, and 8 mg on day 3 DXM 8 mg iv on day 2–3 |
119/173 (68.8%) 85/167 (50.9%) |
53/173 (30.6%) 41/167 (24.6%) |
112/173 (64.7%) 81/167 (48.5%) |
| Toshiaki Takahashi, et al. 2010 [18] | parallelgroup double-blind | 295 | APR 125 mg po + GRA 40 μg/kg iv + DXM 6 mg iv Placebo po + GRA 40 μg/kg iv + DXM 12 mg iv |
APR 80 mg + DXM 4 mg on day 2–3, and APR 80 mg po on day 4–5 Placebo po + DXM 8 mg iv on day 2–3, and placebo po on day 4–5 |
115/146 (78.8%) 79/149 (53.0%) |
51/146 (34.9%) 39/149 (26.2%) |
106/146 (72.6%) 77/149 (51.7%) |
| Zhihuang Hu, et al. 2014 [19] | parallelgroup double-blind | 412 | APR 125 mg po + GRA 3 mg iv + DXM 6 mg po Placebo po + GRA 3 mg iv + DXM 10.5 mg po |
APR 80 mg po + DXM 3.75 mg po on day 2–3, DXM 3.75 mg po on day 4. Placebo po + DXM 7.5 mg po on day 2–3, DXM 7.5 mg po on day 4. |
N/A | N/A | 151/204 (74.0%) 124/208 (59.6%) |
| Steven Grunberg, et al. 2011 [20] | parallelgroup double-blind | 2322 | FOS 150 mg iv + OND 32 mg iv + DXM 12 mg po APR 125 mg po + OND 32 mg iv + DXM 12 mg po |
DXM 8 mg po on day 2, 8 mg po bid on day 3–4 APR 80 mg po + DXM 8 mg po on day 3, DXM 8 mg po on day 4 |
867/1147 (75.6%) 898/1175 (76.4%) |
N/A | 852/1147 (74.3%) 872/1175 (74.2%) |
| Bernardo L Rapoport, et al. 2015 [21] | parallelgroup double-blind | 1070 | ROL 180 mg po + GRA 10 μg/kg iv + DXM 20 mg po GRA 10 μg/kg iv + DXM 20 mg po |
DXM 8 mg po bid DXM 8 mg po bid |
404/535 (75.6%) 340/535 (63.6%) |
298/535 (55.7%) 237/535 (49.9%) |
382/535 (71.4%) 322/535 (60.2%) |
Abbreviations: N/A, no adequate data in relevant trials.
FOS, Fosaprepitant; APR, aprepitant; PAL, palonosetron; OND, ondansetron; GRA, granisetron: DXM, dexamethasone; NETU, netupitant; ROL, rolapitant;
CR, complete response; NN, no nausea; NV, no vomiting.